LTRN GoodMoat Verdict
Full signal breakdown coming soon. Use the X-Ray tool for a detailed analysis.
Lantern Pharma Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Lantern Pharma Inc
Did you know?
Capital expenditures decreased by 86% from FY24 to FY25.
Current Price
$2.23
+5.19%Profile
Valuation (TTM)
Market Cap$24.94M
P/E-1.46
EV—
P/B3.82
Shares Out11.18M
P/Sales—
Revenue$0.00
EV/EBITDA—
Lantern Pharma Inc (LTRN) Quality Analysis
LTRN Profitability
Profitability trend analysis coming soon
LTRN Growth
Growth trend analysis coming soon
LTRN Financial Health
Financial health indicators coming soon
LTRN Quality & Fundamental Analysis
Lantern Pharma Inc (LTRN) is a Healthcare company in the Biotechnology industry, listed on NASDAQ. This quality analysis page evaluates Lantern Pharma Inc's financial health using the Piotroski F-Score methodology, profitability ratios, growth trajectory, and balance sheet strength.
Lantern Pharma Inc has a Piotroski F-Score of N/A out of 9, measuring profitability, leverage, and operating efficiency. and a return on equity (ROE) of -262.00%. Return on assets (ROA) stands at -155.13%.
The debt-to-equity ratio is 0.01, with a current ratio of 2.40.
GoodMoat's quality analysis uses AI-powered insights to evaluate whether Lantern Pharma Inc is a fundamentally sound investment. The GoodMoat Verdict synthesizes profitability, growth, and financial health scores into a clear investment quality rating. Use these metrics alongside valuation tools like the DCF calculator and fair value models to make informed investment decisions.